APO Research
Talk to an analyst

APO RESEARCH · REPORT

Personalized Radioimmunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Personalized Radioimmunotherapy Market Analysis and Forecast 2026-2032

29 December 2025202 pages

Choose your research edition.

Industry ResearchPersonalized Radioimmunotherapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Personalized Radioimmunotherapy Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Personalized Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Personalized Radioimmunotherapy Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Personalized Radioimmunotherapy Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Personalized Radioimmunotherapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Personalized Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Personalized Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Personalized Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Personalized Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Personalized Radioimmunotherapy include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Personalized Radioimmunotherapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Personalized Radioimmunotherapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Personalized Radioimmunotherapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Personalized Radioimmunotherapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Personalized Radioimmunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Personalized Radioimmunotherapy revenue, projected growth trends, production technology, application and end-user industry.

Personalized Radioimmunotherapy Segment by Company

Novartis

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Mundipharma

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Personalized Radioimmunotherapy Segment by Type

Beta-emitting

Targeted Alpha Therapy

Personalized Radioimmunotherapy Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Personalized Radioimmunotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Personalized Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Radioimmunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Personalized Radioimmunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Personalized Radioimmunotherapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Personalized Radioimmunotherapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Personalized Radioimmunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Beta-emitting Major Player Table 3. Targeted Alpha Therapy Major Player Table 4. Global Personalized Radioimmunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Solid Tumor Major Player Table 6. Non Hodgkin Lymphoma Major Player Table 7. Personalized Radioimmunotherapy Industry Trends Table 8. Personalized Radioimmunotherapy Industry Drivers Table 9. Personalized Radioimmunotherapy Industry Opportunities and Challenges Table 10. Personalized Radioimmunotherapy Industry Restraints Table 11. Global Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Personalized Radioimmunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Personalized Radioimmunotherapy Market Share by Region (2021-2026) Table 14. Global Personalized Radioimmunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Personalized Radioimmunotherapy Market Share by Region (2027-2032) Table 16. Global Personalized Radioimmunotherapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Personalized Radioimmunotherapy Revenue Market Share by Players (2021-2026) Table 18. Global Personalized Radioimmunotherapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Personalized Radioimmunotherapy Key Players Headquarters & Area Served Table 20. Global Personalized Radioimmunotherapy Players, Product Type & Application Table 21. Global Personalized Radioimmunotherapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Personalized Radioimmunotherapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Personalized Radioimmunotherapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Personalized Radioimmunotherapy Revenue Market Share by Type (2021-2026) Table 28. Global Personalized Radioimmunotherapy Revenue Market Share by Type (2027-2032) Table 29. Global Personalized Radioimmunotherapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Personalized Radioimmunotherapy Revenue Market Share by Application (2021-2026) Table 33. Global Personalized Radioimmunotherapy Revenue Market Share by Application (2027-2032) Table 34. Novartis Company Information Table 35. Novartis Business Overview Table 36. Novartis Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Novartis Personalized Radioimmunotherapy Product Portfolio Table 38. Novartis Recent Development Table 39. Bayer Company Information Table 40. Bayer Business Overview Table 41. Bayer Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Bayer Personalized Radioimmunotherapy Product Portfolio Table 43. Bayer Recent Development Table 44. Y-mAbs Therapeutics Company Information Table 45. Y-mAbs Therapeutics Business Overview Table 46. Y-mAbs Therapeutics Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Y-mAbs Therapeutics Personalized Radioimmunotherapy Product Portfolio Table 48. Y-mAbs Therapeutics Recent Development Table 49. Telix Pharmaceuticals Company Information Table 50. Telix Pharmaceuticals Business Overview Table 51. Telix Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Telix Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio Table 53. Telix Pharmaceuticals Recent Development Table 54. RadioMedix Company Information Table 55. RadioMedix Business Overview Table 56. RadioMedix Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. RadioMedix Personalized Radioimmunotherapy Product Portfolio Table 58. RadioMedix Recent Development Table 59. Philogen Company Information Table 60. Philogen Business Overview Table 61. Philogen Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Philogen Personalized Radioimmunotherapy Product Portfolio Table 63. Philogen Recent Development Table 64. Orano Med Company Information Table 65. Orano Med Business Overview Table 66. Orano Med Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Orano Med Personalized Radioimmunotherapy Product Portfolio Table 68. Orano Med Recent Development Table 69. Nordic Nanovector Company Information Table 70. Nordic Nanovector Business Overview Table 71. Nordic Nanovector Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nordic Nanovector Personalized Radioimmunotherapy Product Portfolio Table 73. Nordic Nanovector Recent Development Table 74. Mundipharma Company Information Table 75. Mundipharma Business Overview Table 76. Mundipharma Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Mundipharma Personalized Radioimmunotherapy Product Portfolio Table 78. Mundipharma Recent Development Table 79. Lantheus Company Information Table 80. Lantheus Business Overview Table 81. Lantheus Personalized Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Lantheus Personalized Radioimmunotherapy Product Portfolio Table 83. Lantheus Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead Sciences Personalized Radioimmunotherapy Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Fusion Pharmaceuticals Company Information Table 90. Fusion Pharmaceuticals Business Overview Table 91. Fusion Pharmaceuticals Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Fusion Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio Table 93. Fusion Pharmaceuticals Recent Development Table 94. Curium Pharmaceuticals Company Information Table 95. Curium Pharmaceuticals Business Overview Table 96. Curium Pharmaceuticals Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Curium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio Table 98. Curium Pharmaceuticals Recent Development Table 99. Curasight Company Information Table 100. Curasight Business Overview Table 101. Curasight Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Curasight Personalized Radioimmunotherapy Product Portfolio Table 103. Curasight Recent Development Table 104. Clarity Pharmaceuticals Company Information Table 105. Clarity Pharmaceuticals Business Overview Table 106. Clarity Pharmaceuticals Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Clarity Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio Table 108. Clarity Pharmaceuticals Recent Development Table 109. China Isotope & Radiation Company Information Table 110. China Isotope & Radiation Business Overview Table 111. China Isotope & Radiation Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. China Isotope & Radiation Personalized Radioimmunotherapy Product Portfolio Table 113. China Isotope & Radiation Recent Development Table 114. Aurobindo Pharma Company Information Table 115. Aurobindo Pharma Business Overview Table 116. Aurobindo Pharma Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Aurobindo Pharma Personalized Radioimmunotherapy Product Portfolio Table 118. Aurobindo Pharma Recent Development Table 119. Actinium Pharmaceuticals Company Information Table 120. Actinium Pharmaceuticals Business Overview Table 121. Actinium Pharmaceuticals Personalized Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Actinium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio Table 123. Actinium Pharmaceuticals Recent Development Table 124. North America Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 127. North America Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 128. North America Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Personalized Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 130. North America Personalized Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 131. Europe Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Europe Personalized Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 137. Europe Personalized Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 138. China Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 139. China Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 140. China Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 141. China Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 143. Asia Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 144. Asia Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 145. Asia Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 146. Asia Personalized Radioimmunotherapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Asia Personalized Radioimmunotherapy Revenue by Region (US$ Million) & (2021-2026) Table 148. Asia Personalized Radioimmunotherapy Revenue by Region (US$ Million) & (2027-2032) Table 149. SAMEA Personalized Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 150. SAMEA Personalized Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 151. SAMEA Personalized Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 152. SAMEA Personalized Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 153. SAMEA Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. SAMEA Personalized Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 155. SAMEA Personalized Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Personalized Radioimmunotherapy Image Figure 2. Global Personalized Radioimmunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Personalized Radioimmunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Beta-emitting Image Figure 5. Targeted Alpha Therapy Image Figure 6. Global Personalized Radioimmunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Personalized Radioimmunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Solid Tumor Image Figure 9. Non Hodgkin Lymphoma Image Figure 10. Global Personalized Radioimmunotherapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Personalized Radioimmunotherapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Personalized Radioimmunotherapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Personalized Radioimmunotherapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Personalized Radioimmunotherapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Personalized Radioimmunotherapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Personalized Radioimmunotherapy Revenue Market Share by Type (2021-2032) Figure 18. Global Personalized Radioimmunotherapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Personalized Radioimmunotherapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Personalized Radioimmunotherapy Revenue Market Share by Application (2021-2032) Figure 21. North America Personalized Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Personalized Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 23. North America Personalized Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 24. North America Personalized Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 25. United States Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Personalized Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Personalized Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 30. Europe Personalized Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 31. Europe Personalized Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 32. Germany Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Personalized Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Personalized Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 42. China Personalized Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 43. Asia Personalized Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Personalized Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 45. Asia Personalized Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 46. Asia Personalized Radioimmunotherapy Revenue Share by Region (2021-2032) Figure 47. Japan Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Personalized Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Personalized Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Personalized Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Personalized Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 57. Brazil Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Personalized Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Mundipharma
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Personalized Radioimmunotherapy Market by Type
  3. 1.2.1 Global Personalized Radioimmunotherapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Beta-emitting
  5. 1.2.3 Targeted Alpha Therapy
  6. 1.3 Personalized Radioimmunotherapy Market by Application
  7. 1.3.1 Global Personalized Radioimmunotherapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Solid Tumor
  9. 1.3.3 Non Hodgkin Lymphoma
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Personalized Radioimmunotherapy Market Dynamics
  1. 2.1 Personalized Radioimmunotherapy Industry Trends
  2. 2.2 Personalized Radioimmunotherapy Industry Drivers
  3. 2.3 Personalized Radioimmunotherapy Industry Opportunities and Challenges
  4. 2.4 Personalized Radioimmunotherapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Personalized Radioimmunotherapy Market Perspective (2021-2032)
  2. 3.2 Global Personalized Radioimmunotherapy Growth Trends by Region
  3. 3.2.1 Global Personalized Radioimmunotherapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Personalized Radioimmunotherapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Personalized Radioimmunotherapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Personalized Radioimmunotherapy Revenue by Players
  2. 4.1.1 Global Personalized Radioimmunotherapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Personalized Radioimmunotherapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Personalized Radioimmunotherapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Personalized Radioimmunotherapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Personalized Radioimmunotherapy Key Players Headquarters & Area Served
  7. 4.4 Global Personalized Radioimmunotherapy Players, Product Type & Application
  8. 4.5 Global Personalized Radioimmunotherapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Personalized Radioimmunotherapy Market CR5 and HHI
  11. 4.6.3 2025 Personalized Radioimmunotherapy Tier 1, Tier 2, and Tier 3
5 Personalized Radioimmunotherapy Market Size by Type
  1. 5.1 Global Personalized Radioimmunotherapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 5.3 Global Personalized Radioimmunotherapy Revenue Market Share by Type (2021-2032)
6 Personalized Radioimmunotherapy Market Size by Application
  1. 6.1 Global Personalized Radioimmunotherapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  3. 6.3 Global Personalized Radioimmunotherapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Personalized Radioimmunotherapy Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Personalized Radioimmunotherapy Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Y-mAbs Therapeutics
  14. 7.3.1 Y-mAbs Therapeutics Company Information
  15. 7.3.2 Y-mAbs Therapeutics Business Overview
  16. 7.3.3 Y-mAbs Therapeutics Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Y-mAbs Therapeutics Personalized Radioimmunotherapy Product Portfolio
  18. 7.3.5 Y-mAbs Therapeutics Recent Developments
  19. 7.4 Telix Pharmaceuticals
  20. 7.4.1 Telix Pharmaceuticals Company Information
  21. 7.4.2 Telix Pharmaceuticals Business Overview
  22. 7.4.3 Telix Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Telix Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
  24. 7.4.5 Telix Pharmaceuticals Recent Developments
  25. 7.5 RadioMedix
  26. 7.5.1 RadioMedix Company Information
  27. 7.5.2 RadioMedix Business Overview
  28. 7.5.3 RadioMedix Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 RadioMedix Personalized Radioimmunotherapy Product Portfolio
  30. 7.5.5 RadioMedix Recent Developments
  31. 7.6 Philogen
  32. 7.6.1 Philogen Company Information
  33. 7.6.2 Philogen Business Overview
  34. 7.6.3 Philogen Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Philogen Personalized Radioimmunotherapy Product Portfolio
  36. 7.6.5 Philogen Recent Developments
  37. 7.7 Orano Med
  38. 7.7.1 Orano Med Company Information
  39. 7.7.2 Orano Med Business Overview
  40. 7.7.3 Orano Med Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Orano Med Personalized Radioimmunotherapy Product Portfolio
  42. 7.7.5 Orano Med Recent Developments
  43. 7.8 Nordic Nanovector
  44. 7.8.1 Nordic Nanovector Company Information
  45. 7.8.2 Nordic Nanovector Business Overview
  46. 7.8.3 Nordic Nanovector Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Nordic Nanovector Personalized Radioimmunotherapy Product Portfolio
  48. 7.8.5 Nordic Nanovector Recent Developments
  49. 7.9 Mundipharma
  50. 7.9.1 Mundipharma Company Information
  51. 7.9.2 Mundipharma Business Overview
  52. 7.9.3 Mundipharma Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mundipharma Personalized Radioimmunotherapy Product Portfolio
  54. 7.9.5 Mundipharma Recent Developments
  55. 7.10 Lantheus
  56. 7.10.1 Lantheus Company Information
  57. 7.10.2 Lantheus Business Overview
  58. 7.10.3 Lantheus Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lantheus Personalized Radioimmunotherapy Product Portfolio
  60. 7.10.5 Lantheus Recent Developments
  61. 7.11 Gilead Sciences
  62. 7.11.1 Gilead Sciences Company Information
  63. 7.11.2 Gilead Sciences Business Overview
  64. 7.11.3 Gilead Sciences Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Gilead Sciences Personalized Radioimmunotherapy Product Portfolio
  66. 7.11.5 Gilead Sciences Recent Developments
  67. 7.12 Fusion Pharmaceuticals
  68. 7.12.1 Fusion Pharmaceuticals Company Information
  69. 7.12.2 Fusion Pharmaceuticals Business Overview
  70. 7.12.3 Fusion Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Fusion Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
  72. 7.12.5 Fusion Pharmaceuticals Recent Developments
  73. 7.13 Curium Pharmaceuticals
  74. 7.13.1 Curium Pharmaceuticals Company Information
  75. 7.13.2 Curium Pharmaceuticals Business Overview
  76. 7.13.3 Curium Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Curium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
  78. 7.13.5 Curium Pharmaceuticals Recent Developments
  79. 7.14 Curasight
  80. 7.14.1 Curasight Company Information
  81. 7.14.2 Curasight Business Overview
  82. 7.14.3 Curasight Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Curasight Personalized Radioimmunotherapy Product Portfolio
  84. 7.14.5 Curasight Recent Developments
  85. 7.15 Clarity Pharmaceuticals
  86. 7.15.1 Clarity Pharmaceuticals Company Information
  87. 7.15.2 Clarity Pharmaceuticals Business Overview
  88. 7.15.3 Clarity Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Clarity Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
  90. 7.15.5 Clarity Pharmaceuticals Recent Developments
  91. 7.16 China Isotope & Radiation
  92. 7.16.1 China Isotope & Radiation Company Information
  93. 7.16.2 China Isotope & Radiation Business Overview
  94. 7.16.3 China Isotope & Radiation Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  95. 7.16.4 China Isotope & Radiation Personalized Radioimmunotherapy Product Portfolio
  96. 7.16.5 China Isotope & Radiation Recent Developments
  97. 7.17 Aurobindo Pharma
  98. 7.17.1 Aurobindo Pharma Company Information
  99. 7.17.2 Aurobindo Pharma Business Overview
  100. 7.17.3 Aurobindo Pharma Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Aurobindo Pharma Personalized Radioimmunotherapy Product Portfolio
  102. 7.17.5 Aurobindo Pharma Recent Developments
  103. 7.18 Actinium Pharmaceuticals
  104. 7.18.1 Actinium Pharmaceuticals Company Information
  105. 7.18.2 Actinium Pharmaceuticals Business Overview
  106. 7.18.3 Actinium Pharmaceuticals Personalized Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Actinium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
  108. 7.18.5 Actinium Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Personalized Radioimmunotherapy Revenue (2021-2032)
  2. 8.2 North America Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Personalized Radioimmunotherapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Personalized Radioimmunotherapy Revenue by Type (2027-2032)
  5. 8.3 North America Personalized Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Personalized Radioimmunotherapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Personalized Radioimmunotherapy Revenue by Application (2027-2032)
  9. 8.5 North America Personalized Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Personalized Radioimmunotherapy Revenue by Country
  11. 8.6.1 North America Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Personalized Radioimmunotherapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Personalized Radioimmunotherapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Personalized Radioimmunotherapy Revenue (2021-2032)
  2. 9.2 Europe Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Personalized Radioimmunotherapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Personalized Radioimmunotherapy Revenue by Type (2027-2032)
  5. 9.3 Europe Personalized Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Personalized Radioimmunotherapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Personalized Radioimmunotherapy Revenue by Application (2027-2032)
  9. 9.5 Europe Personalized Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Personalized Radioimmunotherapy Revenue by Country
  11. 9.6.1 Europe Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Personalized Radioimmunotherapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Personalized Radioimmunotherapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Personalized Radioimmunotherapy Revenue (2021-2032)
  2. 10.2 China Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 10.2.1 China Personalized Radioimmunotherapy Revenue by Type (2021-2026)
  4. 10.2.2 China Personalized Radioimmunotherapy Revenue by Type (2027-2032)
  5. 10.3 China Personalized Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 10.4 China Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  7. 10.4.1 China Personalized Radioimmunotherapy Revenue by Application (2021-2026)
  8. 10.4.2 China Personalized Radioimmunotherapy Revenue by Application (2027-2032)
  9. 10.5 China Personalized Radioimmunotherapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Personalized Radioimmunotherapy Revenue (2021-2032)
  2. 11.2 Asia Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Personalized Radioimmunotherapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Personalized Radioimmunotherapy Revenue by Type (2027-2032)
  5. 11.3 Asia Personalized Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Personalized Radioimmunotherapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Personalized Radioimmunotherapy Revenue by Application (2027-2032)
  9. 11.5 Asia Personalized Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Personalized Radioimmunotherapy Revenue by Country
  11. 11.6.1 Asia Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Personalized Radioimmunotherapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Personalized Radioimmunotherapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Personalized Radioimmunotherapy Revenue (2021-2032)
  2. 12.2 SAMEA Personalized Radioimmunotherapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Personalized Radioimmunotherapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Personalized Radioimmunotherapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Personalized Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Personalized Radioimmunotherapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Personalized Radioimmunotherapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Personalized Radioimmunotherapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Personalized Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Personalized Radioimmunotherapy Revenue by Country
  11. 12.6.1 SAMEA Personalized Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Personalized Radioimmunotherapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Personalized Radioimmunotherapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst